A groundbreaking medication, this treatment, is sparking considerable buzz amongst healthcare professionals and patients in Australia struggling with obesity . Manufactured by Eli Lilly , Retatrutide functions as a double GIP and GLP-1 receptor agonist, demonstrating impressive potential to aid b